RENIN

RENIN

RENIN Overview

Molecule Name
Renin
Synonyms
REN,FLJ10761,Renin,angiotensinogenase
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs4
Highest Development StageApproved
Target Synonym
REN,Renin,Angiotensinogenase,Angiotensin-Forming Enzyme,Renin Precursor, Renal,HNFJ2,EC:3.4.23.15,EC 3.4.23.15,EC 3.4.23
Background
Renin is also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body's renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2. The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3' UTR. An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.

RENIN Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MT-2765MT-2765Phase 3 ClinicalMitsubishi Tanabe Pharma Corp
Hypertension
Details
SP-20104 (Sarfez Pharmaceuticals)SP-20104Phase 2 Clinical1 A Pharma Gmbh
Glomerulosclerosis, Focal Segmental
Details
Imarikiren hydrochlorideTAK-272; SCO-272Phase 2 ClinicalTakeda Pharmaceutical Co Ltd
Diabetic Nephropathies; Hepatic Insufficiency; Hypertension; Renal Insufficiency
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Aliskiren Hemifumarate/Amlodipine Besilate/HydrochlorothiazideApprovedNovartis Pharma AgRasitrio, AmturnideUnited StatesHypertensionnull2010-12-21
Essential Hypertension; Hypertension
Details
Sitokiren MalateMT-2765; MT2765; I-001; SPH-3127; I001-A; I001-BApprovedMitsubishi Tanabe Pharma, Shanghai Pharmaceuticals Holding Co Ltd信妥安Mainland ChinaEssential HypertensionShanghai Sine Pharmaceutical Laboratories Co Ltd2025-12-03
Colitis, Ulcerative; Diabetic Nephropathies; Essential Hypertension; Hypertension; Kidney Diseases; Psoriasis
Details
Aliskiren HemifumarateCGP-60536; SPP-100; SPP-100B; SPP-100A; CGP-60536BApprovedNovartis Pharma AgSprimeo, Enviage, Tekturna, Riprazo, 锐思力, RasilezUnited StatesHypertensionNoden Pharma Dac2007-03-05
Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Essential Hypertension; Glomerulonephritis, IGA; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Myocardial Ischemia; Overweight
Details
AliskirenApprovedMainland ChinaEssential HypertensionNovartis Pharma Ag2010-03-26
Essential Hypertension
Details